Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06494488 · ClinicalTrials.gov registry record · Early Phase 1
Differential Thrombogenesis by EPA and DHA Mediated by HDL
A Early Phase 1 study of Hypertriglyceridemia and Lipid Metabolism Disorders, sponsored by The Miriam Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06494488 is a Early Phase 1 study of Hypertriglyceridemia and Lipid Metabolism Disorders that is actively recruiting participants, run by The Miriam Hospital. The registered enrollment target is 80 participants, below the 173-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06494488, a Early Phase 1 study of Hypertriglyceridemia and Lipid Metabolism Disorders, is actively recruiting participants, sponsored by The Miriam Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels. The purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Participants will: Visit the clinic 3 times during study checkups, tests and blood collection. Randomized to either the EPA or the DHA supplementation group. Be given a 28-day food and activity log.
Conditions Studied
Interventions
- DRUG EPA
- DRUG DHA
Study Locations (1)
Rhode Island
- Brown University Health - Lipid Clinic - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2028-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06494488
The ClinicalTrials.gov registry entry for NCT06494488 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 173-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (54% lower). The listed sponsor is The Miriam Hospital, which has 136 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which EPA is the first listed.
NCT06494488 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06494488 about?
NCT06494488 is a clinical study titled "Differential Thrombogenesis by EPA and DHA Mediated by HDL". The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels. The purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoi...
What is the current status of trial NCT06494488?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2025-07-10. Estimated completion is 2028-03-31.
What conditions does trial NCT06494488 study?
This clinical trial studies the following conditions: Hypertriglyceridemia, Lipid Metabolism Disorders.
What interventions are being tested in trial NCT06494488?
The interventions under investigation include: EPA (DRUG), DHA (DRUG).
Who is sponsoring clinical trial NCT06494488?
This trial is sponsored by The Miriam Hospital, which has 136 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06494488 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
RECRUITING · Phase 3
-
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
RECRUITING · Phase 2
-
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
ACTIVE NOT RECRUITING · Phase 1
-
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
ACTIVE NOT RECRUITING · Phase 2
-
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.